WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock

Crit Care Med. 2006 Aug;34(8):2188-93. doi: 10.1097/01.CCM.0000227173.13497.56.

Abstract

Objective: To determine the effect of an estrogen receptor-beta selective agent in experimental models of systemic infection and sepsis.

Design: WAY-202196, a nonsteroidal selective estrogen receptor-beta agonist, was tested in the murine listeriosis model, the neutropenic rat Pseudomonas aeruginosa infection, and the mouse cecal ligation and puncture sepsis models.

Setting: University-affiliated biomedical research laboratory.

Subjects: BALB/c mice and Sprague-Dawley rats.

Interventions: WAY-202196 or control (vehicle) was administered orally in doses ranging from 1.5 to 50 mg/kg at various time points in the three experimental model systems.

Measurements and main results: Susceptibility of mice treated with a single oral dose of up to 50 mg/kg WAY-202196 did not differ from those treated with vehicle alone after systemic challenge by Listeria monocytogenes, suggesting a lack of generalized immunosuppression. In the neutropenic rat model, daily administration of WAY-202196 (50 mg/kg) significantly increased survival against an otherwise lethal challenge of P. aeruginosa 12.4.4 compared with the control group (83% vs. 25% survival; p < 0.05). Preservation of intestinal mucosal weight and prevention of histopathologic changes were also observed with the administration of WAY-202196. Similar results were obtained in a cecal ligation and puncture model, in which multiple oral doses of WAY-202196 (50 mg/kg) improved survival (83% vs. 0%; p < 0.05), preserved intestinal epithelial integrity, and significantly reduced systemic bacteremia and peritoneal interleukin-6 and tumor necrosis factor levels. The estrogen receptor-beta agonist provided a comparable level of protection in both male and female animals.

Conclusion: These results indicate that oral administration of WAY-202196 preserved gastrointestinal barrier function and improved outcome in experimental models of systemic infection and inflammation. WAY-202196 and similar agents may prove useful clinically as a novel treatment strategy for the treatment or prevention of severe sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Ascitic Fluid / metabolism
  • Bacteremia / drug therapy
  • Bacteremia / microbiology
  • Disease Models, Animal
  • Estrogen Receptor beta / agonists
  • Female
  • Interleukin-6 / metabolism
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / ultrastructure
  • Listeria monocytogenes
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Naphthols / pharmacology*
  • Neutropenia / complications
  • Pseudomonas Infections / drug therapy
  • Rats
  • Rats, Sprague-Dawley
  • Shock, Septic / drug therapy*
  • Shock, Septic / microbiology
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Estrogen Receptor beta
  • Interleukin-6
  • Naphthols
  • Tumor Necrosis Factor-alpha
  • 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxy-1-naphthonitrile